Literature DB >> 12816889

Neurogenesis in cerebral heterotopia induced in rats by prenatal methylazoxymethanol treatment.

Giorgio Battaglia1, Silvia Pagliardini, Laura Saglietti, Flaminio Cattabeni, Monica Di Luca, Stefania Bassanini, Veronica Setola.   

Abstract

We have previously demonstrated that the antiproliferative agent methylazoxymethanol acetate (MAM) is able to induce in rats cerebral heterotopia that share striking similarities with those observed in human periventricular nodular heterotopia (PNH), a cerebral dysgenesis frequently observed in human patients affected by drug-resistant focal epilepsy. In this study, we investigated the time-course of neurogenesis in the cerebral heterotopia of MAM-treated rats, with the idea of understanding why PNH develop in human patients. For these goals, we analyzed the cytoarchitectural features, the time of neurogenesis and the cellular phenotype of the heterotopia, by means of BrdU immunocytochemistry and confocal immunofluorescence experiments. Our data demonstrate that the different types of heterotopia in MAM-treated rats are formed through the same altered neurogenetic process, which follows quite organized neurogenetic gradients. The MAM-induced ablation of an early wave of cortical neurons is sufficient to alter per se the migration and differentiation of subsequently generated neurons, which in turn set the base for the formation of the different heterotopic structures. The neurogenesis of MAM-induced heterotopia may explain the origin and intrinsic epileptogenicity of periventricular nodular heterotopia in human patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12816889     DOI: 10.1093/cercor/13.7.736

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  8 in total

1.  Initiation of epileptiform activity in a rat model of periventricular nodular heterotopia.

Authors:  Naranzogt Tschuluun; H Jürgen Wenzel; Emily T Doisy; Philip A Schwartzkroin
Journal:  Epilepsia       Date:  2011-09-20       Impact factor: 5.864

2.  Embryonic and early postnatal abnormalities contributing to the development of hippocampal malformations in a rodent model of dysplasia.

Authors:  Mercedes Paredes; Samuel J Pleasure; Scott C Baraban
Journal:  J Comp Neurol       Date:  2006-03-01       Impact factor: 3.215

3.  Prenatal exposure to thalidomide, altered vasculogenesis, and CNS malformations.

Authors:  K L Hallene; E Oby; B J Lee; S Santaguida; S Bassanini; M Cipolla; N Marchi; M Hossain; G Battaglia; D Janigro
Journal:  Neuroscience       Date:  2006-07-20       Impact factor: 3.590

4.  Early cerebrovascular and parenchymal events following prenatal exposure to the putative neurotoxin methylazoxymethanol.

Authors:  Stefania Bassanini; Kerri Hallene; Giorgio Battaglia; Adele Finardi; Stefano Santaguida; Marilyn Cipolla; Damir Janigro
Journal:  Neurobiol Dis       Date:  2007-03-03       Impact factor: 5.996

5.  Combined effects of prenatal inhibition of vasculogenesis and neurogenesis on rat brain development.

Authors:  Q Y Fan; S Ramakrishna; N Marchi; Vincent Fazio; Kerri Hallene; D Janigro
Journal:  Neurobiol Dis       Date:  2008-09-30       Impact factor: 5.996

6.  The etiological role of blood-brain barrier dysfunction in seizure disorders.

Authors:  Nicola Marchi; William Tierney; Andreas V Alexopoulos; Vikram Puvenna; Tiziana Granata; Damir Janigro
Journal:  Cardiovasc Psychiatry Neurol       Date:  2011-03-30

7.  Developmental learning impairments in a rodent model of nodular heterotopia.

Authors:  Steven W Threlkeld; Courtney A Hill; Caitlin E Cleary; Dongnhu T Truong; Glenn D Rosen; R Holly Fitch
Journal:  J Neurodev Disord       Date:  2009-07-16       Impact factor: 4.025

8.  Structural changes in the neocortex as correlates of variations in EEG spectra and seizure susceptibility in rat brains with different degrees of dysplasia.

Authors:  Zuzanna Setkowicz; Kinga Gzielo; Michal Kielbinski; Krzysztof Janeczko
Journal:  J Comp Neurol       Date:  2021-12-22       Impact factor: 3.028

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.